静脉输注免疫球蛋白在儿童川崎病中应用的专家共识

2021-09-15 中国儿科相关医学专家组(统称) 中国当代儿科杂志. 2021,23(09)

川崎病是一种好发于5岁以下儿童的急性自限性血管炎性疾病。静脉输注免疫球蛋白(intravenous immunoglobulin,IVIG)已经成为一种有效的治疗方案,可以有效减少心血管并发症的发生率

中文标题:

静脉输注免疫球蛋白在儿童川崎病中应用的专家共识

发布日期:

2021-09-15

简要介绍:

川崎病是一种好发于5岁以下儿童的急性自限性血管炎性疾病。静脉输注免疫球蛋白(intravenous immunoglobulin,IVIG)已经成为一种有效的治疗方案,可以有效减少心血管并发症的发生率,但目前国内外尚无儿童川崎病IVIG应用共识或临床指南。该共识是基于目前国内外关于儿童川崎病中IVIG应用的研究进展,同时参考国内外川崎病的诊疗指南,并经过制定专家充分讨论而形成。该共识对IVIG在儿童川崎病中的临床应用策略及其不良反应的防治提出了具体建议。[中国当代儿科杂志,2021,23 (9):867-876]
 

相关资料下载:
[AttachmentFileName(sort=1, fileName=静脉输注免疫球蛋白在儿童川崎病中应用的专家共识_杜忠东.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f42ea1c002191ed0, title=静脉输注免疫球蛋白在儿童川崎病中应用的专家共识, enTitle=, guiderFrom=中国当代儿科杂志. 2021,23(09), authorId=0, author=, summary=川崎病是一种好发于5岁以下儿童的急性自限性血管炎性疾病。静脉输注免疫球蛋白(intravenous immunoglobulin,IVIG)已经成为一种有效的治疗方案,可以有效减少心血管并发症的发生率, cover=https://img.medsci.cn/2021923/1632409050012_2020535.jpg, journalId=0, articlesId=null, associationId=924, associationName=中国儿科相关医学专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Sep 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="row"><span id="ChDivSummary" class="abstract-text" style="color: #666666;">川崎病是一种好发于5岁以下儿童的急性自限性血管炎性疾病。静脉输注免疫球蛋白(intravenous immunoglobulin,IVIG)已经成为一种有效的治疗方案,可以有效减少心血管并发症的发生率,但目前国内外尚无儿童川崎病IVIG应用共识或临床指南。该共识是基于目前国内外关于儿童川崎病中IVIG应用的研究进展,同时参考国内外川崎病的诊疗指南,并经过制定专家充分讨论而形成。该共识对IVIG在儿童川崎病中的临床应用策略及其不良反应的防治提出了具体建议。[中国当代儿科杂志,2021,23 (9):867-876]</span></div> <div class="row">&nbsp;</div>, tagList=[TagDto(tagId=9477, tagName=川崎病)], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=9477, guiderKeyword=川崎病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4371, appHits=241, showAppHits=0, pcHits=607, showPcHits=4123, likes=0, shares=20, comments=18, approvalStatus=1, publishedTime=Thu Sep 23 23:40:40 CST 2021, publishedTimeString=2021-09-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Sep 23 22:57:39 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:11:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=静脉输注免疫球蛋白在儿童川崎病中应用的专家共识_杜忠东.pdf)])
静脉输注免疫球蛋白在儿童川崎病中应用的专家共识_杜忠东.pdf
下载请点击:
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1242462, encodeId=2e35124246256, content=指南很详细,感谢梅斯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73252505952, createdName=124ac1bem02暂无昵称, createdTime=Thu Sep 01 12:11:03 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193639, encodeId=5b541193639a6, content=打开之后看不见, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220215/2bdc00e661fa46358c98ccaf47216fbb.jpeg, type=image, width=750, height=1334)], authenticateStatus=null, createdAvatar=, createdBy=0c265190892, createdName=147182a8m57暂无昵称, createdTime=Tue Feb 15 16:16:21 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060524, encodeId=0bd4106052417, content=打不开啊,友友们都能看吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/1a30d67f3d4f46858c5436d5b29bfa02/c20e1e5b903f4cc8845f5da6ba7394ae.jpg, createdBy=ab3f5602140, createdName=花白, createdTime=Thu Oct 14 18:47:35 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073550, encodeId=2bd910e3550be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40d75721324, createdName=红樱桃与白萝卜, createdTime=Wed Nov 24 15:56:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059219, encodeId=f746105921958, content=川崎病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/c56681ddc31c4bd4a5911801095fdf8a/fd23b96ae1244b55a3bd7f6d6a79d0e7.jpg, createdBy=56e15596007, createdName=ms6000001253705830, createdTime=Sun Oct 10 17:21:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2022-09-01 124ac1bem02暂无昵称

    指南很详细,感谢梅斯

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1242462, encodeId=2e35124246256, content=指南很详细,感谢梅斯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73252505952, createdName=124ac1bem02暂无昵称, createdTime=Thu Sep 01 12:11:03 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193639, encodeId=5b541193639a6, content=打开之后看不见, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220215/2bdc00e661fa46358c98ccaf47216fbb.jpeg, type=image, width=750, height=1334)], authenticateStatus=null, createdAvatar=, createdBy=0c265190892, createdName=147182a8m57暂无昵称, createdTime=Tue Feb 15 16:16:21 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060524, encodeId=0bd4106052417, content=打不开啊,友友们都能看吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/1a30d67f3d4f46858c5436d5b29bfa02/c20e1e5b903f4cc8845f5da6ba7394ae.jpg, createdBy=ab3f5602140, createdName=花白, createdTime=Thu Oct 14 18:47:35 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073550, encodeId=2bd910e3550be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40d75721324, createdName=红樱桃与白萝卜, createdTime=Wed Nov 24 15:56:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059219, encodeId=f746105921958, content=川崎病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/c56681ddc31c4bd4a5911801095fdf8a/fd23b96ae1244b55a3bd7f6d6a79d0e7.jpg, createdBy=56e15596007, createdName=ms6000001253705830, createdTime=Sun Oct 10 17:21:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1242462, encodeId=2e35124246256, content=指南很详细,感谢梅斯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73252505952, createdName=124ac1bem02暂无昵称, createdTime=Thu Sep 01 12:11:03 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193639, encodeId=5b541193639a6, content=打开之后看不见, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220215/2bdc00e661fa46358c98ccaf47216fbb.jpeg, type=image, width=750, height=1334)], authenticateStatus=null, createdAvatar=, createdBy=0c265190892, createdName=147182a8m57暂无昵称, createdTime=Tue Feb 15 16:16:21 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060524, encodeId=0bd4106052417, content=打不开啊,友友们都能看吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/1a30d67f3d4f46858c5436d5b29bfa02/c20e1e5b903f4cc8845f5da6ba7394ae.jpg, createdBy=ab3f5602140, createdName=花白, createdTime=Thu Oct 14 18:47:35 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073550, encodeId=2bd910e3550be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40d75721324, createdName=红樱桃与白萝卜, createdTime=Wed Nov 24 15:56:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059219, encodeId=f746105921958, content=川崎病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/c56681ddc31c4bd4a5911801095fdf8a/fd23b96ae1244b55a3bd7f6d6a79d0e7.jpg, createdBy=56e15596007, createdName=ms6000001253705830, createdTime=Sun Oct 10 17:21:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-14 花白

    打不开啊,友友们都能看吗

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1242462, encodeId=2e35124246256, content=指南很详细,感谢梅斯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73252505952, createdName=124ac1bem02暂无昵称, createdTime=Thu Sep 01 12:11:03 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193639, encodeId=5b541193639a6, content=打开之后看不见, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220215/2bdc00e661fa46358c98ccaf47216fbb.jpeg, type=image, width=750, height=1334)], authenticateStatus=null, createdAvatar=, createdBy=0c265190892, createdName=147182a8m57暂无昵称, createdTime=Tue Feb 15 16:16:21 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060524, encodeId=0bd4106052417, content=打不开啊,友友们都能看吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/1a30d67f3d4f46858c5436d5b29bfa02/c20e1e5b903f4cc8845f5da6ba7394ae.jpg, createdBy=ab3f5602140, createdName=花白, createdTime=Thu Oct 14 18:47:35 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073550, encodeId=2bd910e3550be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40d75721324, createdName=红樱桃与白萝卜, createdTime=Wed Nov 24 15:56:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059219, encodeId=f746105921958, content=川崎病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/c56681ddc31c4bd4a5911801095fdf8a/fd23b96ae1244b55a3bd7f6d6a79d0e7.jpg, createdBy=56e15596007, createdName=ms6000001253705830, createdTime=Sun Oct 10 17:21:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-11-24 红樱桃与白萝卜

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1242462, encodeId=2e35124246256, content=指南很详细,感谢梅斯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73252505952, createdName=124ac1bem02暂无昵称, createdTime=Thu Sep 01 12:11:03 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193639, encodeId=5b541193639a6, content=打开之后看不见, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220215/2bdc00e661fa46358c98ccaf47216fbb.jpeg, type=image, width=750, height=1334)], authenticateStatus=null, createdAvatar=, createdBy=0c265190892, createdName=147182a8m57暂无昵称, createdTime=Tue Feb 15 16:16:21 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060524, encodeId=0bd4106052417, content=打不开啊,友友们都能看吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/1a30d67f3d4f46858c5436d5b29bfa02/c20e1e5b903f4cc8845f5da6ba7394ae.jpg, createdBy=ab3f5602140, createdName=花白, createdTime=Thu Oct 14 18:47:35 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073550, encodeId=2bd910e3550be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40d75721324, createdName=红樱桃与白萝卜, createdTime=Wed Nov 24 15:56:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059219, encodeId=f746105921958, content=川崎病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/c56681ddc31c4bd4a5911801095fdf8a/fd23b96ae1244b55a3bd7f6d6a79d0e7.jpg, createdBy=56e15596007, createdName=ms6000001253705830, createdTime=Sun Oct 10 17:21:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 ms6000001253705830

    川崎病

    0

拓展阅读

2012 川崎病冠状动脉病变的临床处理建议

中华医学会儿科学分会心血管学组 · 2012-10-01

日本川崎病心血管后遗症诊断和管理指南(JCS 2013)

日本循环学会(JCS,Japanese Circulation Society) · 2014-09-22

2017 AHA科学声明:川崎病的诊断,治疗和长期管理

美国心脏病学会(ACC,American College of Cardiology) · 2017-03-29

2018 欧洲共识建议:川崎病的诊断和治疗

国外风湿免疫科相关专家小组 · 2018-12-07

2020 JCS/JSCS指南:川崎病心血管后遗症的诊断和管理

日本循环学会(JCS,Japanese Circulation Society) · 2020-07-08

2021 SIP建议:川崎病的综合管理(修订版)

意大利儿科学会(Italian Pediatric Society) · 2021-01-25